Combinational Treatment of Imatinib and Allicin Synergistically Inhibits the Growth of BCR-ABL-Positive Leukemia and the Emergence of Drug-Resistant Cells

被引：0
|
作者：
Lim, Jamie
Kim, Jung-Hyun
Ahn, Eun-Young Erin
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4992
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Imatinib restores expression of CD62L in BCR-ABL-positive cells
    Fruehauf, S
    Topaly, J
    Schad, M
    Paschka, P
    Gschaidmeier, H
    Zeller, WJ
    Hochhaus, A
    Ho, AD
    JOURNAL OF LEUKOCYTE BIOLOGY, 2003, 73 (05) : 600 - 603
  • [22] BCL-2 antisense oligonuicleotide genasense is active against imatinib-resistant BCR-ABL-positive cells
    Tauchi, T
    Sumi, M
    Nakajima, A
    Sashida, G
    Shimamoto, T
    Ohyashiki, K
    CLINICAL CANCER RESEARCH, 2003, 9 (11) : 4267 - 4273
  • [23] Specific inhibition of hTERT by shRNA sensitizes for imatinib mesylate in BCR-ABL-positive cells.
    Sashida, G
    Tauchi, T
    Sumi, M
    Nakajima, A
    Ohyashiki, JH
    Ohyashiki, K
    BLOOD, 2004, 104 (11) : 169B - 169B
  • [24] Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia
    Mizuta, Shuichi
    Matsuo, Keitaro
    Nishiwaki, Satoshi
    Imai, Kiyotoshi
    Kanamori, Heiwa
    Ohashi, Kazuteru
    Fukuda, Takahiro
    Onishi, Yasushi
    Miyamura, Koichi
    Takahashi, Satoshi
    Onizuka, Makoto
    Atsuta, Yoshiko
    Suzuki, Ritsuro
    Morishima, Yasuo
    Kato, Koji
    Sakamaki, Hisashi
    Tanaka, Junji
    BLOOD, 2014, 123 (15) : 2325 - 2332
  • [25] Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib
    Mor-Tzuntz, Rahav
    Uziel, Orit
    Shpilberg, Ofer
    Lahav, Judith
    Raanani, Pia
    Balchanashvili, Mary
    Rabizadeh, Esther
    Zimra, Yael
    Lahav, Meir
    Granot, Galit
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (01) : 27 - 37
  • [26] In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines
    La Rosée, P
    Johnson, K
    Corbin, AS
    Stoffregen, EP
    Moseson, EM
    Willis, S
    Mauro, MM
    Melo, JV
    Deininger, MW
    Druker, BJ
    BLOOD, 2004, 103 (01) : 208 - 215
  • [27] Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia
    Zhang, Xin
    Jia, Deyong
    Ao, Junping
    Liu, Huijuan
    Zang, Yi
    Azam, Mohammad
    Habib, Samy L.
    Li, Jia
    Ruan, Xinsen
    Jia, Hao
    Wang, Xueying
    Li, Baojie
    ONCOTARGET, 2016, 7 (43) : 69945 - 69960
  • [28] Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
    Bandyopadhyay, Shovik
    Li, Junjie
    Traer, Elie
    Tyner, Jeffrey W.
    Zhou, Amy
    Oh, Stephen T.
    Cheng, Ji-Xin
    PLOS ONE, 2017, 12 (07):
  • [29] The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
    Deininger, MWN
    Goldman, JM
    Lydon, N
    Melo, JV
    BLOOD, 1997, 90 (09) : 3691 - 3698
  • [30] Detection of BCR-ABL-Positive Cells in the Colostrum of a Pregnant Patient with Chronic Myeloid Leukemia
    Hiroshima, Yuki
    Tajima, Katsushi
    Shiono, Yousuke
    Suzuki, Ikuko
    Kouno, Kei
    Katou, Yuuichi
    Kato, Takeo
    INTERNAL MEDICINE, 2011, 50 (20) : 2389 - 2391
12345